Contraindications and Precautions for GLP-1 Receptor Agonists

Absolute Contraindications

• The American College of Cardiology recommends that GLP-1 receptor agonists are contraindicated in patients with a personal or family history of medullary thyroid carcinoma, due to the association with thyroid C-cell tumors in rodent studies 1, 2
• The American College of Cardiology states that GLP-1 receptor agonists are contraindicated in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN2), due to the increased risk of medullary thyroid carcinoma 2
• The American College of Cardiology advises that a history of serious hypersensitivity reaction to the specific GLP-1 receptor agonist is a contraindication for further use 1, 2
• The American College of Cardiology recommends that exenatide and lixisenatide are contraindicated in patients with severe renal impairment or end-stage renal disease (eGFR <30 mL/min/1.73m²) 1, 3

Agent-Specific Contraindications

• Exenatide is contraindicated in severe renal impairment (eGFR <30 mL/min/1.73m²) or end-stage renal disease, and is not recommended for patients on dialysis 3
• Lixisenatide is contraindicated in severe renal impairment (eGFR <30 mL/min/1.73m²) and should be avoided if eGFR <15 mL/min/1.73m² 3

Cautions and Relative Contraindications

• The American College of Cardiology recommends using liraglutide with caution in patients with a history of pancreatitis 1, 2
• The American College of Cardiology advises using liraglutide and semaglutide with caution in patients with severe renal impairment or end-stage renal disease 1, 4
• Clinically meaningful gastroparesis is a relative contraindication for shorter-acting GLP-1 receptor agonists, which may delay gastric emptying 1, 2
• Prior gastric surgery requires careful consideration when using GLP-1 receptor agonists 1
• Semaglutide has been associated with diabetic retinopathy complications, particularly with rapid glucose reduction 1
• GLP-1 receptor agonists are contraindicated during pregnancy 5

Important Considerations for Concomitant Medications

• The American College of Cardiology recommends that when GLP-1 receptor agonists are used with insulin or insulin secretagogues, the dose of these agents may need to be reduced to minimize the risk of hypoglycemia 1, 4
• Oral medications with a narrow therapeutic index may be affected by delayed gastric emptying caused by shorter-acting GLP-1 receptor agonists 1, 2

Common Adverse Effects to Monitor

• Gastrointestinal symptoms, such as nausea, vomiting, and diarrhea, occur in 15-20% of patients, particularly with semaglutide having the highest risk 4
• Increased heart rate, typically by approximately 5 beats per minute, is a common adverse effect 4

Clinical Pearls

• GLP-1 receptor agonists with proven cardiovascular benefit, such as liraglutide, semaglutide, and dulaglutide, are preferred agents for patients with type 2 diabetes and established cardiovascular disease 4
• These medications do not cause hypoglycemia when used alone but may increase the risk when combined with insulin or sulfonylureas 4
• Dose titration can help minimize gastrointestinal side effects 4

GLP-1 Receptor Agonist Safety and Efficacy at GFR 51

Agent-Specific Recommendations

• The American College of Endocrinology recommends liraglutide, dulaglutide, and semaglutide as preferred agents that require no dose adjustment at a GFR of 51 mL/min/1.73 m² 6, 7
• The Endocrine Society suggests that exenatide be used with caution when initiating or escalating doses at a GFR of 51 mL/min/1.73 m², as its clearance is reduced by 36% at GFR 45 mL/min/1.73 m² 6, 7, 8, 9, 10
• The American Diabetes Association recommends monitoring eGFR when initiating or escalating doses of semaglutide and dulaglutide 6, 7

Important Monitoring Parameters

• The National Kidney Foundation advises monitoring eGFR when initiating or escalating doses of GLP-1 receptor agonists, particularly with semaglutide and dulaglutide, to minimize the risk of adverse reactions 6, 7

Common Pitfalls to Avoid

• The Kidney Disease Outcomes Quality Initiative (KDOQI) guideline suggests avoiding confusion between older 2012 guidance and current evidence, as the 2020 Endocrine Reviews guideline and FDA labeling now confirm that no dose adjustment is needed for liraglutide at a GFR of 51 mL/min/1.73 m² 6, 7, 8, 9, 10

GLP-1 Receptor Agonist Prescribing Thresholds Based on GFR

Agent-Specific GFR Contraindications

• The American Journal of Kidney Diseases recommends that exenatide is contraindicated when eGFR <30 mL/min/1.73 m² and should not be used in end-stage renal disease or patients on dialysis 11
• Exenatide clearance is reduced by 36% at eGFR 45 mL/min/1.73 m² and by 64% at eGFR 30 mL/min/1.73 m² 11
• The Mayo Clinic recommends that liraglutide, dulaglutide, and semaglutide require no dose adjustment and can be used even when eGFR <20 mL/min/1.73 m² 12, 13, 14
• Liraglutide is fully degraded elsewhere in the body with kidneys not being a major organ of elimination 11
• The 2022 Mayo Clinic guidelines specifically recommend weekly dulaglutide or semaglutide, or daily liraglutide as preferred agents when eGFR <20 mL/min/1.73 m² 12, 13

Clinical Algorithm for GLP-1 Selection Based on Renal Function

• When eGFR ≥30 mL/min/1.73 m², all GLP-1 receptor agonists can be prescribed, according to the American Journal of Kidney Diseases and Diabetes Care 11, 14
• The Mayo Clinic and Diabetes Care recommend prioritizing agents with proven cardiovascular and kidney benefits: liraglutide, semaglutide, or dulaglutide 12, 14
• When eGFR 20-29 mL/min/1.73 m², the American Journal of Kidney Diseases recommends not prescribing exenatide or lixisenatide 11
• Liraglutide, dulaglutide, or semaglutide are safe and preferred when eGFR 20-29 mL/min/1.73 m², according to the Mayo Clinic 12, 13
• When eGFR <20 mL/min/1.73 m², the Mayo Clinic recommends weekly dulaglutide or semaglutide, or daily liraglutide as preferred agents 12, 13

Important Safety Considerations

• Exenatide has been associated with acute kidney injury or acceleration of CKD progression in case reports, according to the American Journal of Kidney Diseases 11

Common Pitfalls to Avoid

• The American Journal of Kidney Diseases and Mayo Clinic recommend not relying on outdated 2012 KDOQI guidelines that recommended avoiding liraglutide when GFR <60 mL/min/1.73 m² 11, 12, 13, 14
• Exenatide and lixisenatide have absolute contraindications at eGFR <30 mL/min/1.73 m² due to renal clearance, according to the American Journal of Kidney Diseases 11

GLP‑1 Receptor Agonist Use in Chronic Pancreatitis with Structural Changes

Structural Characteristics of Chronic Pancreatitis and Their Clinical Meaning

• Chronic pancreatitis is defined by irreversible morphological alterations such as pancreatic duct dilatation, glandular atrophy, and cyst formation, indicating ongoing pancreatic inflammation and injury【15】.
• The presence of duct dilatation, atrophy, and cystic lesions in a patient with chronic pancreatitis signifies active pancreatic damage and should be regarded as a contraindication to agents that further stimulate the pancreas【15】.

Endocrine and Exocrine Consequences of Chronic Pancreatitis

• Patients with chronic pancreatitis frequently develop diabetes mellitus due to progressive loss of β‑cell function; insulin therapy is often required to achieve glycaemic control in this setting【15】【16】.
• Pancreatic exocrine insufficiency (PEI) is common when atrophy and ductal dilatation are present; initiating pancreatic enzyme replacement therapy (PERT) helps mitigate fat malabsorption and supports nutritional status【15】.
• Clinical monitoring for PEI should include assessment for fatty diarrhoea, bloating, abdominal cramping, and unintended weight loss【15】.

Preferred Glucose‑Lowering Strategies in the Context of Chronic Pancreatitis

SGLT2 Inhibitors

• Sodium‑glucose cotransporter‑2 (SGLT2) inhibitors, which have demonstrated cardiovascular and renal benefits, should be prioritized for individuals with type 2 diabetes who also have cardiovascular disease or chronic kidney disease【17】【18】.
• SGLT2 inhibitors provide organ protection comparable to GLP‑1 receptor agonists but without the pancreatic safety concerns associated with the latter【18】.

Metformin

• Metformin remains the first‑line oral agent for type 2 diabetes when estimated glomerular filtration rate (eGFR) is ≥30 mL/min/1.73 m²【17】.

DPP‑4 Inhibitors

• Dipeptidyl‑peptidase‑4 (DPP‑4) inhibitors offer incretin‑based glucose control with a lower degree of direct pancreatic stimulation, representing a safer alternative to GLP‑1 receptor agonists in this population【16】.

Summary of Evidence Strength

• The cited data on structural disease characteristics and endocrine/exocrine consequences derive from a 2017 review in Proceedings of the Nutrition Society (expert consensus/observational evidence)【15】.
• Recommendations for SGLT2 inhibitors and metformin are based on large‑scale clinical trials and guideline‑level evidence reported in Kidney International (2022) and Diabetes Care (2019)【17】【18】.
• The safety profile of DPP‑4 inhibitors is supported by a 2012 Diabetes Care publication (clinical trial data)【16】.